(ALNY) Alnylam Pharmaceuticals - Ratings and Ratios
ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, Leqvio
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 46.3% |
| Value at Risk 5%th | 65.8% |
| Relative Tail Risk | -13.50% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.15 |
| Alpha | 42.92 |
| CAGR/Max DD | 0.47 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.459 |
| Beta | 0.920 |
| Beta Downside | 1.020 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.61% |
| Mean DD | 16.27% |
| Median DD | 16.21% |
Description: ALNY Alnylam Pharmaceuticals December 03, 2025
Alnylam Pharmaceuticals (NASDAQ: ALNY) is a Cambridge-based biotech that commercializes RNA-interference (RNAi) medicines and runs an extensive pipeline targeting rare and common diseases. Its approved portfolio includes ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, OXLUMO for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
The company’s late-stage pipeline features vutrisiran (Phase III for ATTR-cardiomyopathy), Fitusiran (Phase III for hemophilia), and cemdisiran (Phase III for myasthenia gravis, PNH, and geographic atrophy). Early-stage programs span metabolic, neuro-degenerative, and oncology indications, including ALN-HTT02 (Phase I Huntington’s disease) and ALN-SOD (Phase II ALS).
Key financial and market metrics (Q3 2024): revenue of $1.12 billion, driven primarily by Leqvio ($310 million) and ONPATTRO ($210 million); a 30 % year-over-year revenue growth rate; and a cash runway extending beyond 2027 under current spending levels. The RNAi therapeutic market is projected to expand at a ~15 % CAGR through 2030, positioning Alnylam as a leading beneficiary of both rare-disease premium pricing and emerging indications with larger patient populations.
Strategic collaborations with Regeneron, Roche, Sanofi, Novartis, and others provide co-development funding and broaden commercial reach, while the company’s 2024-2025 guidance assumes a 12-15 % increase in total sales, contingent on successful Phase III readouts and regulatory approvals.
For a deeper, data-driven assessment of Alnylam’s valuation and risk profile, you may find the analytical tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (43.6m TTM) > 0 and > 6% of Revenue (6% = 192.6m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA 4.18pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 74.68% (prev 101.9%; Δ -27.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 265.9m > Net Income 43.6m (YES >=105%, WARN >=100%) |
| Net Debt (1.28b) to EBITDA (186.5m) ratio: 6.88 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.54 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (137.3m) change vs 12m ago 6.81% (target <= -2.0% for YES) |
| Gross Margin 83.99% (prev 85.37%; Δ -1.39pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 70.89% (prev 49.82%; Δ 21.07pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.80 (EBITDA TTM 186.5m / Interest Expense TTM 162.3m) >= 6 (WARN >= 3) |
Altman Z'' -3.01
| (A) 0.49 = (Total Current Assets 3.95b - Total Current Liabilities 1.56b) / Total Assets 4.85b |
| (B) -1.48 = Retained Earnings (Balance) -7.16b / Total Assets 4.85b |
| warn (B) unusual magnitude: -1.48 — check mapping/units |
| (C) 0.03 = EBIT TTM 130.2m / Avg Total Assets 4.53b |
| (D) -1.56 = Book Value of Equity -7.18b / Total Liabilities 4.62b |
| Total Rating: -3.01 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 61.68
| 1. Piotroski 4.0pt |
| 2. FCF Yield 0.39% |
| 3. FCF Margin 6.90% |
| 4. Debt/Equity 11.86 |
| 5. Debt/Ebitda 6.88 |
| 6. ROIC - WACC (= 2.39)% |
| 7. RoE 26.13% |
| 8. Rev. Trend 90.99% |
| 9. EPS Trend 75.52% |
What is the price of ALNY shares?
Over the past week, the price has changed by -13.22%, over one month by -12.19%, over three months by -14.67% and over the past year by +62.09%.
Is ALNY a buy, sell or hold?
- Strong Buy: 12
- Buy: 12
- Hold: 7
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the ALNY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 492.2 | 23.8% |
| Analysts Target Price | 492.2 | 23.8% |
| ValueRay Target Price | 484.8 | 21.9% |
ALNY Fundamental Data Overview December 10, 2025
P/E Trailing = 1433.3999
P/E Forward = 48.5437
P/S = 17.6979
P/B = 242.8946
P/EG = -0.49
Beta = 0.298
Revenue TTM = 3.21b USD
EBIT TTM = 130.2m USD
EBITDA TTM = 186.5m USD
Long Term Debt = 1.04b USD (from longTermDebt, last quarter)
Short Term Debt = 160.4m USD (from shortTermDebt, last quarter)
Debt = 2.77b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.28b USD (from netDebt column, last quarter)
Enterprise Value = 56.86b USD (56.81b + Debt 2.77b - CCE 2.72b)
Interest Coverage Ratio = 0.80 (Ebit TTM 130.2m / Interest Expense TTM 162.3m)
FCF Yield = 0.39% (FCF TTM 221.4m / Enterprise Value 56.86b)
FCF Margin = 6.90% (FCF TTM 221.4m / Revenue TTM 3.21b)
Net Margin = 1.36% (Net Income TTM 43.6m / Revenue TTM 3.21b)
Gross Margin = 83.99% ((Revenue TTM 3.21b - Cost of Revenue TTM 514.0m) / Revenue TTM)
Gross Margin QoQ = 84.21% (prev 81.52%)
Tobins Q-Ratio = 11.72 (Enterprise Value 56.86b / Total Assets 4.85b)
Interest Expense / Debt = 1.60% (Interest Expense 44.4m / Debt 2.77b)
Taxrate = -5.07% (negative due to tax credits) (-12.1m / 239.0m)
NOPAT = 136.8m (EBIT 130.2m * (1 - -5.07%)) [negative tax rate / tax credits]
Current Ratio = 2.54 (Total Current Assets 3.95b / Total Current Liabilities 1.56b)
Debt / Equity = 11.86 (Debt 2.77b / totalStockholderEquity, last quarter 233.9m)
Debt / EBITDA = 6.88 (Net Debt 1.28b / EBITDA 186.5m)
Debt / FCF = 5.80 (Net Debt 1.28b / FCF TTM 221.4m)
Total Stockholder Equity = 166.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.90% (Net Income 43.6m / Total Assets 4.85b)
RoE = 26.13% (Net Income TTM 43.6m / Total Stockholder Equity 166.8m)
RoCE = 10.79% (EBIT 130.2m / Capital Employed (Equity 166.8m + L.T.Debt 1.04b))
RoIC = 11.44% (NOPAT 136.8m / Invested Capital 1.20b)
WACC = 9.05% (E(56.81b)/V(59.58b) * Re(9.41%) + D(2.77b)/V(59.58b) * Rd(1.60%) * (1-Tc(-0.05)))
Discount Rate = 9.41% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.57%
[DCF Debug] Terminal Value 64.53% ; FCFE base≈139.2m ; Y1≈91.4m ; Y5≈41.8m
Fair Price DCF = 5.03 (DCF Value 664.0m / Shares Outstanding 132.1m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 75.52 | EPS CAGR: 78.03% | SUE: 1.78 | # QB: 1
Revenue Correlation: 90.99 | Revenue CAGR: 52.20% | SUE: 2.10 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.09 | Chg30d=-0.166 | Revisions Net=+1 | Analysts=5
EPS next Year (2026-12-31): EPS=10.61 | Chg30d=-0.345 | Revisions Net=+2 | Growth EPS=+113.8% | Growth Revenue=+42.8%
Additional Sources for ALNY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle